1. Home
  2. FLC vs GBIO Comparison

FLC vs GBIO Comparison

Compare FLC & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Flaherty & Crumrine Total Return Fund Inc

FLC

Flaherty & Crumrine Total Return Fund Inc

HOLD

Current Price

$17.43

Market Cap

181.5M

Sector

Finance

ML Signal

HOLD

Logo Generation Bio Co.

GBIO

Generation Bio Co.

HOLD

Current Price

$5.47

Market Cap

36.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FLC
GBIO
Founded
2003
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
181.5M
36.3M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
FLC
GBIO
Price
$17.43
$5.47
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$8.88
AVG Volume (30 Days)
37.8K
72.1K
Earning Date
01-01-0001
11-05-2025
Dividend Yield
6.64%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$15,270,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.62
$3.00
52 Week High
$15.45
$12.40

Technical Indicators

Market Signals
Indicator
FLC
GBIO
Relative Strength Index (RSI) 54.93 45.94
Support Level $17.39 $5.31
Resistance Level $17.60 $5.77
Average True Range (ATR) 0.16 0.19
MACD 0.02 -0.01
Stochastic Oscillator 62.77 23.08

Price Performance

Historical Comparison
FLC
GBIO

About FLC Flaherty & Crumrine Total Return Fund Inc

Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

Share on Social Networks: